Retatrutide vs Wegovy: Which One Produces More Weight Loss?
Wegovy (semaglutide) has been the dominant weight loss medication since its fda approval in 2021, with the landmark STEP trial program demonstrating an average 14.9% weight loss at 68 weeks. Retatrutide, Eli Lilly’s triple-agonist peptide, has produced the highest weight loss numbers ever recorded in a Phase 3 obesity trial — an average 28.3% at 80 weeks in the TRIUMPH-1 study. The question of which is stronger for weight loss has a clear answer based on the clinical data, but the full picture involves differences in side effect profiles, dosing schedules, availability, and cost that matter significantly for anyone choosing between them.
The comparison is not entirely fair because the two drugs are at different stages of development. Wegovy is FDA-approved, widely prescribed, covered by many insurance plans, and available at pharmacies. Retatrutide is still in Phase 3 clinical trials and is not yet approved by the FDA. The retatrutide data comes from clinical trial settings with strict protocols, while Wegovy’s real-world effectiveness data includes millions of patients with varying adherence levels. The TRIUMPH results are exceptionally promising, but they represent best-case clinical trial outcomes rather than real-world results.
Mechanism Comparison: Dual Agonist vs Triple Agonist
The fundamental difference between retatrutide and Wegovy is the number of hormone receptors they target. Wegovy is a GLP-1 receptor agonist — it targets one receptor. Retatrutide is a triple agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. This difference in mechanism is the primary reason for the gap in weight loss outcomes. Wegovy’s single-target approach produces appetite suppression through GLP-1 activation. Retatrutide adds GIP activation for improved insulin sensitivity and reduced nausea, plus glucagon receptor activation that increases energy expenditure through lipolysis.
The glucagon component is particularly significant for weight loss comparison. In the Phase 2 retatrutide trial published in The Lancet in 2023, researchers measured resting energy expenditure and found that the 12 mg retatrutide dose increased it by approximately 10% compared to placebo. Wegovy does not increase resting energy expenditure — its weight loss effects come entirely from reduced caloric intake through appetite suppression. This means retatrutide users burn more calories at rest than Wegovy users, even when consuming the same number of calories. A 10% increase in resting energy expenditure translates to approximately 150 to 200 additional calories burned per day for an average adult, which compounds into significant additional weight loss over months of treatment.
Clinical Trial Outcomes Head to Head
The STEP program for Wegovy and the TRIUMPH program for retatrutide used different trial designs, which makes direct comparison imperfect but still informative. The STEP 1 trial showed an average 14.9% weight loss with semaglutide 2.4 mg weekly at 68 weeks. The TRIUMPH-1 trial showed an average 22.3% weight loss with retatrutide 8 mg weekly at 80 weeks, and an average 28.3% with the 12 mg dose. The retatrutide 4 mg dose — the lowest therapeutic dose in the trial — produced weight loss comparable to the maximum Wegovy dose, demonstrating that even the entry-level retatrutide dose matches the best that semaglutide can achieve.
The proportion of participants achieving specific weight loss thresholds further illustrates the difference. In the STEP 1 trial, approximately 70% of Wegovy participants lost at least 10% of their body weight. In TRIUMPH-1, 93% of retatrutide participants lost at least 10% of their body weight at the 12 mg dose. One in five Wegovy participants lost at least 20% of their body weight. For retatrutide, more than half of participants lost at least 20% of their body weight. These differences are large enough to represent genuinely different treatment outcomes rather than statistical noise.
Side Effect Profile Comparison
The additional weight loss with retatrutide comes with a higher side effect burden. Gastrointestinal side effects are the most common adverse events for both drugs, but they occur at higher rates and with greater severity in retatrutide users. The TRIUMPH data shows that nausea affects approximately 35% of retatrutide users at the 12 mg dose, compared to approximately 25% of Wegovy users. Vomiting rates are 10-15% for retatrutide versus 5-8% for Wegovy. Diarrhea rates are similar at approximately 15% for both. The dose-escalation phase is the most challenging period for both drugs, but retatrutide’s more aggressive mechanism produces a more intense gastrointestinal response during the first 4 to 8 weeks.
The trade-off is clear: retatrutide produces approximately double the weight loss of Wegovy but with a higher rate of gastrointestinal side effects. For users who tolerate GLP-1 drugs well, the additional benefit may be worth the increased side effect burden. For users who are sensitive to gastrointestinal side effects, Wegovy may be the more practical choice even though the weight loss is lower. The individual variation in GLP-1 tolerance is significant — some people experience minimal side effects on high-dose retatrutide while others struggle with standard-dose Wegovy. There is currently no way to predict individual tolerance before starting treatment.
Availability and Cost Differences
This is where the comparison becomes less theoretical and more practical. Wegovy is available now by prescription at pharmacies across the United States. The list price is approximately $1,350 per month, but insurance coverage varies widely — many plans cover Wegovy for weight loss when specific BMI criteria are met. Manufacturer savings programs can reduce the out-of-pocket cost to as little as $25 per month for eligible patients with commercial insurance. Medicare and Medicaid coverage for weight loss medications is inconsistent and depends on the specific plan.
Retatrutide is not yet FDA-approved and is not available by prescription. The only people who currently have access to retatrutide are participants in the ongoing TRIUMPH clinical trials. Eli Lilly expects to submit a New Drug Application to the FDA in late 2026 or early 2027, with potential FDA approval in 2027 or 2028 assuming the Phase 3 data meets regulatory standards. For anyone considering weight loss treatment in the near term, Wegovy is the practical choice because it is available now. Retatrutide represents a future option that may be significantly more effective but requires patience and ongoing clinical development.
Leave a Reply